Compare SMX & NCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMX | NCEL |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Ireland | Switzerland |
| Employees | 19 | 4 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.7M | 20.6M |
| IPO Year | N/A | N/A |
| Metric | SMX | NCEL |
|---|---|---|
| Price | $16.30 | $3.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.8M | 31.5K |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $1.83 |
| 52 Week High | $490.00 | $5.12 |
| Indicator | SMX | NCEL |
|---|---|---|
| Relative Strength Index (RSI) | 68.63 | 52.22 |
| Support Level | $15.39 | $3.03 |
| Resistance Level | $20.09 | $3.54 |
| Average True Range (ATR) | 2.10 | 0.26 |
| MACD | 0.73 | -0.01 |
| Stochastic Oscillator | 92.42 | 55.71 |
SMX (Security Matters) PLC provides one solution to solve both authentication and track and trace challenges in order to uphold supply chain integrity and provide quality assurance and brand accountability to producers of goods. Its technology works as a track and trace system using a marker, a reader, and an algorithm to identify embedded sub-molecular particles in order to track and trace different components along a production process (or any other marked good along a supply chain) to the end producer.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.